Experimental pill tested to fight lung infections in cystic fibrosis
NCT ID NCT02649751
Summary
This study tested whether an experimental oral drug called roscovitine is safe for adults with cystic fibrosis who have a common genetic mutation and a chronic lung infection. Researchers gave different doses to 24 participants over 28 days, while 12 others received a placebo, to check for side effects and see if it reduced bacteria or inflammation. The trial was terminated early, and its main goal was to gather preliminary safety data to inform future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Lyon Sud
Lyon, 69495, France
-
CHR - Hôpital Calmette
Lille, 59037, France
-
CHU Nantes
Nantes, 44093, France
-
CHU de Bordeaux - Hôpital Haut-Lévêque
Pessac, France, 33604, France
-
CHU de Nice - Hôpital Pasteur
Nice, France, 06001, France
-
Centre Hospitalier Bretagne Atlantique
Vannes, France, 56017, France
-
Centre de Perharidy
Roscoff, 29684, France
-
Centre de Ressources et de Compétences de la mucoviscidose
Reims, France, 51100, France
-
Hôpital Arnaud de Villeneuve
Montpellier, 34295, France
-
Hôpital Cochin
Paris, 75014, France
-
Hôpital Larrey
Toulouse, 30030, France
Conditions
Explore the condition pages connected to this study.